Search clinical trials for: Booster-MVA-BN® Filo or saline placebo

Total 30 results

University of Maryland, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust; Leidos Biomedical Research, Inc...

Completed

Phase 1 Trial of Ebola Vaccine in Mali

Ebola Virus Disease | Hemorrhagic Fever

Mali
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Healthy

United States
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust

Completed

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Ebola | Ebola Zaire

United Kingdom
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaborators

Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Hemorrhagic Fever, Ebola

Kenya, Uganda, Burkina Faso, Côte D'Ivoire
Janssen Vaccines & Prevention B.V.
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Hemorrhagic Fever, Ebola

United States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
Crucell Holland BV

Completed

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United Kingdom
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

Smallpox

Germany
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; University...

Completed

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Ebola Viral Disease

France, United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United States
Crucell Holland BV

Completed

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Kenya
Crucell Holland BV

Completed

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Tanzania, Uganda
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone)

Ebola Virus Disease

Sierra Leone
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
University of Oxford

Terminated

Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine

Influenza

United Kingdom
Crucell Holland BV

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Innovaderm Research Inc.
Merck Sharp & Dohme LLC

Terminated

Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy

Psoriasis

Canada
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, Bulgaria, Czechia, Hu... and more
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Herpes Zoster

China
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Herpes Zoster

China
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Cervical Cancer

Japan, United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer

United States, Germany, Israel, Canada, China, Australia, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Russian Federation, Turkey and more
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Poland, Korea, Republic of, United States, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Indivior Inc.

Completed

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

Opioid Use Disorder

United States
University Hospital, Tours
University Hospital, Rouen; Central Hospital, Nancy, France; Poitiers University... and other collaborators

Completed

Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (TRULIGHT)

HIV

France
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
MRC/UVRI and LSHTM Uganda Research Unit
King's College London; Karolinska Institutet; Gilead Sciences; Imperial College... and other collaborators

Enrolling by invitation

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PrEPVacc)

HIV Infections

Uganda

Search clinical trials for: Booster-MVA-BN® Filo or saline placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations